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Abstract 
Aims 
Polypharmacy is associated with adverse events and multimorbidity, but data are limited on its 
association with specific comorbidities in primary care settings. We measured the prevalence of 
polypharmacy and inappropriate prescribing, and assessed the association of polypharmacy with 
specific comorbidities. 
Methods 
We did a cross-sectional analysis of 1002 patients aged 50-80 years followed in Swiss university 
primary care settings. We defined polypharmacy as ≥5 long-term prescribed drugs and multimorbidity as 
≥2 comorbidities. We used logistic mixed-effects regression to assess the association of polypharmacy 
with the number of comorbidities, multimorbidity, specific sets of comorbidities, potentially inappropriate 
prescribing (PIP) and potential prescribing omission (PPO). We used multilevel mixed-effects Poisson 
regression to assess the association of the number of drugs with the same parameters. 
Results 
Patients (mean age 63.5 years, 67.5% ≥2 comorbidities, 37.0% ≥5 drugs) had a mean of 3.9 (range 0-
17) drugs. Age, BMI, multimorbidity, hypertension, diabetes mellitus, chronic kidney disease, and 
cardiovascular diseases were independently associated with polypharmacy. The association was 
particularly strong for hypertension (OR 8.49, 95%CI 5.25-13.73), multimorbidity (OR 6.14, 95%CI 4.16-
9.08), and oldest age (75-80 years: OR 4.73, 95%CI 2.46-9.10 vs.50-54 years). The prevalence of PPO 
was 32.2% and PIP was more frequent among participants with polypharmacy (9.3% vs. 3.2%, 
p<0.006). 
Conclusions 
Polypharmacy is common in university primary care settings, is strongly associated with hypertension, 
diabetes mellitus, chronic kidney disease and cardiovascular diseases, and increases potentially 
inappropriate prescribing. Multimorbid patients should be included in further trials for developing 
adapted guidelines and avoiding inappropriate prescribing.  
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Introduction 
With the increasing life expectancy worldwide, a higher proportion of individuals not only get older [1], 
but are also more likely to develop multiple chronic conditions [2-4]. Most chronic conditions 
(comorbidities) are covered by disease-specific clinical guidelines using a single disease framework; 
this leads physicians to recommend drug treatments for each condition separately, which may lead to 
polypharmacy and drug-drug and drug-disease interactions [5]. In addition, to lower the risk of 
developing future medical conditions, research in preventive medicine has uncovered multiple risk 
factors, particularly in cardiovascular medicine, that also need treatment, thus increasing the number of 
people on regular multiple drug therapy [6, 7]. Furthermore, patients are often seen by multiple 
specialist physicians who prescribe drugs that primary care physicians are often reluctant to stop 
[8].Polypharmacy, commonly defined as the concurrent use of 5 or more long-term prescribed drugs, is 
frequent and increasing in prevalence [4, 7, 9-14]. The use of multiple drugs is associated with potential 
unforeseen medical consequences, such as adverse drug events, drug monitoring errors, unplanned 
hospitalizations, and sometimes fatal outcomes [5, 15-19]. The risk of drug-drug interaction increases 
with the number of prescribed drugs: 13% of patients on 2 concurrent drugs experience drug-drug 
interaction, but this risk rises to 38% for those on 5 drugs and 82% for those on ≥7 drugs [20]. 
Moreover, polypharmacy is associated with poor adherence, lower physical and social function, higher 
healthcare costs, and decreased quality of life [13, 16, 19]. Additionally, inappropriate prescribing, 
including both over- (potentially inappropriate prescribing [PIP]) and underprescription (potential 
prescribing omission [PPO]) is also associated with poor outcome, such as increase in adverse drug 
events [21]. While polypharmacy is relatively well defined, the definition of multimorbidity is not 
consistent in the literature; a common definition is 2 or more comorbidities [3]. 
Prior epidemiological studies conducted in several other countries found a prevalence of polypharmacy 
ranging from 12 to 48% in patients aged 50 years or older [9, 10, 13, 14, 22], but data remain limited on 
associations between polypharmacy and specific comorbidities, like cardiovascular ones [13]. In 
Switzerland, a country with universal healthcare coverage, only one study assessed the prevalence of 
polypharmacy and PIP, based on claims data from a health insurer company without clinical information 
on diagnosis. Except for this study, data on PIP and PPO in Switzerland are limited, with studies 
including only hospitalized geriatric [23] or mentally-ill patients [24].  
We therefore aimed to measure the prevalence of polypharmacy, PIP and PPO in university primary 
care settings, and to assess the association of polypharmacy with specific comorbidities, in order to 
uncover subgroups of patients at higher risk of polypharmacy. 
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Material and methods 
 
Study population 
We abstracted medical records from 1002 randomly selected patients followed for at least one year by 
primary care physicians in all but one Swiss university primary care clinics (Basel, Geneva, Lausanne 
and Zurich) in a retrospective cohort study, as previously described [25]. For this analysis, we used 
cross-sectional data of the baseline visit. These community-dwelling patients were randomly identified 
from electronic administrative data of all patients aged 50 to 80 years and followed in 2005-2006. The 
selection was limited to this age group to ensure a high prevalence of cardiovascular risk factors and 
other conditions that are targeted by preventive care and medical treatment. About 90% of the patients 
were cared for by residents in general internal medicine supervised by senior physicians. The remaining 
10% were cared by senior physicians directly.  
We initially identified 1889 patients, among which 54 charts could not be found, probably because the 
patients had left the clinic for another ambulatory practice. We excluded 125 patients because they had 
no outpatient visit to a primary care physician, and 117 that were followed only in a specialized care 
setting during this period. In order to ensure adequate time and information to assess preventive care, 
we excluded another 591 patients who had less than one year follow-up in the university primary care 
setting during the review period. 
 
Definitions of polypharmacy and multimorbidity 
We recorded only long-term prescribed drugs at the first visit of the review period; prescriptions for 
acute conditions, like antibiotics or temporary painkillers, were not taken into account. Similarly to 
previous studies, we defined polypharmacy as 5 or more long-term prescribed drugs [9, 12, 14, 26, 27]. 
We found no consistent definition to select comorbidities in prior scientific literature [28]. The length of 
comorbidity lists ranged from 7 to 46 different comorbidities [13, 29-31]. We therefore established a new 
list including 17 comorbidities (Table A), as previously described [32], based on a large study by Higashi 
et al. [33] and on the Charlson index [34]. We added psychiatric conditions (e.g. schizophrenia, 
depression) as an important comorbidity [35], based on a consensus of the above mentioned references 
and between the authors. Additionally, we defined specific subgroups of comorbidities: 1) 
cardiovascular diseases: history of transient ischemic attack, cerebral vascular accident, coronary artery 
disease, angina, myocardial infarction, congestive heart failure and/or peripheral vascular disease; 2) 
chronic pulmonary diseases: chronic obstructive pulmonary disease, asthma, sleep apnea syndrome, 
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sarcoidosis, pulmonary hypertension, bronchiectases, interstitial pulmonary disease and/or global 
respiratory insufficiency; 3) psychiatric diseases: depression, bipolar disorder, psychosis, schizophrenia 
and/or pervasive development disorder. For sensitivity analyses, we used subcategories of 
cardiovascular disease (cerebral vascular disease, ischemic heart disease, heart failure). As did others 
[3, 29], we defined multimorbidity as the presence of 2 or more of these comorbidities [32], but also 
assessed the number of comorbidities as a count variable. 
 
Potentially inappropriate prescribing and potentially prescribing omission 
PIP and PPO were measured using the Screening Tool of Older People’s Prescriptions (STOPP) and 
the Screening Tool to Alert doctors to Right Treatment (START) criteria [36]. As the criteria were 
developed for individuals aged ≥65 years, we applied them to this subgroup of our patients, and then 
performed a sensitivity analysis including our whole population. As we had detailed clinical information 
on cardiovascular disease and cardiovascular risk factors, we only applied the STOPP/START criteria 
for cardiovascular and anti-diabetic drugs when all detailed clinical information was available. Therefore, 
we applied 7 STOPP (i.e. A3, B3, B6, C1, C7, J1, J2) and 4 START (i.e. A3, A4, A5, A7) criteria related 
to these drugs. One author (CEA) checked the whole database for PIP and PPO. A 5% random sample 
was checked for accuracy by a second author (SS). The agreement between the 2 reviewers was 
98.0% and the 2.0% disagreement was solved by discussion. PIP and PPO were defined as the 
percentage of patients with at least 1 unfulfilled STOPP and START criteria, respectively.  
 
Statistical Analyses 
We counted the number of drugs as a whole (0, 1, 2, 3, 4, 5, 6, 7, 8, 9, ≥10), as well as stratified by 5-
year age groups and by the number of comorbidities (0, 1, 2, 3-4, 5-6, ≥7). We compared baseline 
characteristics between patients with and those without polypharmacy using t-test and chi-square test 
where appropriate.  
We used a logistic mixed-effects regression model, crude and adjusted for age, gender, civil status and 
occupation, to assess the association of polypharmacy with the number of comorbidities, presence of 
multimorbidity, smoking status, body mass index (BMI), specific comorbidities, subgroups of 
comorbidities (psychiatric diseases, dementia, cardiovascular diseases, diabetes mellitus, hypertension, 
chronic pulmonary diseases, cancer and chronic kidney disease), PIP and PPO. Results were 
presented as odds ratio (OR) with 95% confidence intervals (CI).  
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We used a multilevel mixed-effects Poisson regression model, crude and adjusted for the same 
parameters, to assess the association between the number of drugs as a count variable with the same 
variables as in the previous model. Results were presented as incidence rate ratios (IRR) with 95%CI.  
We used the mixed-effects models to account for the clustering of patients within the different treating 
physicians and treatment centers. We performed all statistical analyses using STATA release 13.1 
(StataCorp, College Station, TX). All p-values were 2-sided at a 0.05 level of significance. 
 
Results 
 
Patients characteristics 
Table 1 shows baseline characteristics of the study population by presence or absence of 
polypharmacy. Mean age (standard deviation [SD]) was 63.5 (8.3) years and 44.4% were women. Most 
patients (55.9%) were Swiss and 37.9% were retired. The majority (67.5%) of patients had 
multimorbidity and the mean number of comorbidities was 2.6, ranging from 0 to 10. Almost every 
patient (91.1%) had at least 1 drug, 37.0% had polypharmacy and 4.1% had at least 10 drugs. The 
maximum number of different drugs taken by a single patient was 17. 
 
The association between polypharmacy, number of drugs and age 
Figure 1a shows the percentage of patients on a particular number of drugs according to age group. 
Patients with polypharmacy were significantly older than patients on less than 5 drugs (p<0.0001, Table 
1). The prevalence of polypharmacy was 20.8% (41/197) in the youngest age group (50-54 years), 
45.6% (194/426) in the patients aged 65 years or older, and 54.8% (63/115) in the oldest age group (75-
80 years). The oldest age group had the highest odds for polypharmacy compared to the youngest age 
group in adjusted analysis (OR 4.73, 95% CI 2.46-9.10, Table 2). In the highest age group, the number 
of drugs was 29% higher than in the lowest age group (IRR 1.29, 95% CI 1.07-1.56, Table 3). 
 
The association of polypharmacy, number of drugs and comorbidities 
The number of drugs increased significantly with the number of comorbidities. In patients with 4 or more 
comorbidities, all but 2 patients (9.2%) had at least 1 drug. Among the patients with at least 7 
comorbidities, 84.9% had polypharmacy (Figure 1b). This association remained significant in 
multivariate analyses; even after adjustment for demographics, patients with multimorbidity had a far 
higher odds for polypharmacy (OR 6.14, 95% CI 4.16-9.08, Table 2) and an increased number of drugs 
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(IRR 1.91, 95% CI 1.72-2.13, Table 3) compared to patients without multimorbidity. For each additional 
comorbidity, patients were more likely to have more prescribed drugs (IRR 1.18, 95% CI 1.15-1.20). 
Hypertension had the strongest association with polypharmacy (OR 8.49, 95% CI 5.25-13.73) and the 
number of drugs (IRR 2.10, 95% CI 1.87-2.36). Cardiovascular diseases, diabetes mellitus, BMI and 
chronic kidney disease were also independently associated with polypharmacy and the number of drugs 
(Tables 2 and 3). Chronic pulmonary diseases were weakly associated with the number of drugs, but 
not with polypharmacy (Tables 2 and 3). Psychiatric diseases, dementia and cancer were associated 
neither with polypharmacy nor with the number of drugs. The OR (95%CI) for polypharmacy was 2.63 
(1.56-4.46) in patients with cerebral vascular disease, 3.96 (2.75-5.71) in patients with ischemic heart 
disease, and 14.32 (5.75-35.66) in patients with heart failure. 
 
Polypharmacy, number of drugs and other clinical variables 
Being employed was associated with a lower number of drugs when compared with other social status 
(on social aid, unemployed, at home, in education, or retired), and with a lower prevalence of 
polypharmacy when compared with being on social aid or unemployed (Tables 2 and 3). These 
associations were less strong after adjusting for the number of comorbidities (data not shown). Civil 
status was associated neither with polypharmacy nor with the number of drugs. Finally, male gender 
was only slightly associated with the number of drugs, but not with polypharmacy (Tables 2 and 3). 
 
Potentially inappropriate prescribing and potentially prescribing omission 
Table 4 describes the prevalence of each STOPP/START criterion in patients aged ≥65 years and in the 
whole patient population. In patients aged ≥65 years, the prevalence of PIP was 5.9%; it was higher 
among patients with polypharmacy (9.3% versus 3.0% in those without, p=0.006, Table 1) and strongly 
associated with polypharmacy (OR 3.72, 95% CI 1.47-9.44, Table 2) and with the number of drugs (IRR 
1.35, 95% CI 1.12-1.64, Table 3). Almost one third (32.2%) of the patients had PPO. PPO was 
associated neither with polypharmacy nor with the number of drugs (Tables 2 and 3). Forty-eight 
patients had more than 1 PPO. Omitting antiplatelet (START criterion A3) and statin (START criterion 
A5) therapies with a documented history of coronary, cerebral, or peripheral vascular disease were the 
2 most prevalent PPO, accounting for 70.7% of the PPOs. We found similar results in the whole study 
population (Tables 2, 3 and 4). 
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Discussion  
In this random sample of primary care patients aged 50-80 years, we found that 37% had 
polypharmacy, and 4% received 10 drugs or more. The prevalence of PIP was significantly higher 
among patients with polypharmacy. Multimorbidity, age, and specific comorbidities, such as 
hypertension, diabetes mellitus, chronic kidney disease and cardiovascular diseases, were associated 
with polypharmacy, while other subgroups of comorbidities (psychiatric diseases, dementia, chronic 
pulmonary diseases, cancer) were not. The association was particularly strong for hypertension.  
The prevalence of polypharmacy in our study was consistent with prior epidemiological studies 
conducted in other high income countries in patients aged 50 years or older: a large Swedish study 
found a prevalence of polypharmacy of 12-38% in the age group 50-79 years [9], while it ranged from 
13 to 48% for the same age range in a study using electronic primary care records in Scotland [13], and 
was 29% in patients aged 57-85 years in the USA [14]. When focusing on patients aged 65 years or 
older, the prevalence of polypharmacy in our study (46%) was also consistent with previous data from 
an Italian community-dwelling population (46%) [22].  
The strong association of multimorbidity and the number of comorbidities with polypharmacy and the 
number of drugs is consistent with previous data [13, 14, 31]. This may reflect the disease-specific 
guidelines that are still usually applied for initiating drug treatments. However, patients with 
multimorbidity are often excluded from, and less than 5% explicitly included in randomized controlled 
trials on which these recommendations are based [37]; thus, applying them to these patients may be 
inappropriate [19, 38]. The strong association between PIP and polypharmacy is consistent with 
previous data using the same criteria for PIP [23]. This observation highlights the importance to 
reconsider each prescription in patients receiving polypharmacy. For this purpose, the STOPP/START 
criteria may help [36, 39]; however, as the application of the whole criteria set is time-consuming and 
therefore difficult to implement in everyday clinical practice, software solutions are under development. 
Finally, physician’s clinical judgment and shared decision making are central in the process of 
prescription. 
The United Kingdom Prospective Diabetes Study (UKPDS) in patients with type 2 diabetes showed that 
29% of the patients needed at least 3 different drugs to reach a blood pressure target of <150/85mmHg 
[40], while the recommended goal in this population is far lower (<130/80mmHg) [41]. Additionally, 
because hypertension, diabetes mellitus and chronic kidney disease are strongly related to 
cardiovascular diseases, patients with these comorbidities often receive additional drugs recommended 
in both primary and secondary prevention (e.g. aspirin, statins) [19, 42-44]. The association of these 
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cardiovascular risk factors and cardiovascular diseases with polypharmacy is consistent with previous 
data [13, 45]. Interestingly, we found a stronger association of polypharmacy with hypertension than 
with cardiovascular disease. The interpretation of this finding is limited by our broad classification of 
cardiovascular disease, which was associated with some heterogeneity (e.g. stronger association of 
polypharmacy with heart failure than with stroke). 
Surprisingly, we found no association between polypharmacy and psychiatric disorders. This probably 
reflects the reality of patients cared in ambulatory general internal medicine. Psychiatric conditions that 
are mostly managed with drugs (e.g. schizophrenia) [46] were indeed rather rare (6% of the patients 
having a psychiatric condition in our study had schizophrenia), while more prevalent conditions like 
personality disorder (25% of the patients having a psychiatric condition in our study) are often managed 
without any drug as first line therapy. On the other hand, patients followed in specialized psychiatric 
settings may have more severe conditions needing multiple medications, thus polypharmacy may be 
more prevalent among them. We also found no association with dementia, but our study included only 
24 patients with this condition. Preventive drugs might have been discontinued in these patients with 
formally diagnosed dementia, as dementia is associated with shortened life expectancy and decreased 
quality of life [47].  
In our study, there was no significant association between cancer and polypharmacy, which is 
consistent with the study by Payne et al. (12) that found a similar mean number of drugs among this 
subgroup of patients (4 drugs). On the opposite, a review of previous studies in patients with advanced 
cancer showed a high prevalence of polypharmacy among them [48]. This discrepancy is probably due 
to different settings (in-hospital versus ambulatory) and study population (advanced versus not 
advanced cancer).  
Patients who were unemployed, receiving social aid, at home, in education or retired, were prescribed a 
higher number of drugs than patients that were employed. Interestingly, this association was stronger 
for patients unemployed or receiving social aid than for patients being at home, in education or retired. 
This finding may be partially explained by a higher number of comorbidities, as the association of 
occupation status and polypharmacy was weakened by adjusting for the number of comorbidities. This 
is consistent with data showing a higher prevalence of multimorbidity in the most deprived population, 
among which multimorbidity would occur on average 10 to 15 years earlier [3]. However, as this 
association didn’t disappear after adjustment for the number of comorbidities, we can hypothesize 
additional explanations for this finding: deprived patients may have lower income and/or education, 
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which has been associated with polypharmacy [10, 13, 49];  they may also more likely consult with a 
prescription purpose, as suggested previously [49].  
Although the community-dwelling individuals in our study differed from older frail nursing home 
residents, those with multimorbidity are at higher risk of polypharmacy as they become older. Although 
the patterns of drugs are different in nursing home and in the community, e.g. with a higher number of 
pain-killers and psychotropic drugs [50-52], optimizing medication in the community-dwelling individuals 
is also central in order to optimize care and reduce polypharmacy. 
There are some limitations to our study. First, our results are based on retrospective medical chart 
review, with potential underreporting; however, a previous study comparing process-based quality 
scores using standardized patients, clinical vignettes and abstraction of medical charts found that 
measurement of quality of care using abstraction of medical charts was about 5% lower than using 
clinical vignettes and 10% lower than using standardized patients [53]. Second, we restricted our 
analyses to patients aged 50 to 80 years and can therefore not draw conclusions for younger or older 
patients. Third, as we could apply a subset of the STOPP/START criteria only, we could not compare 
the prevalence of PIP and PPO with data of other previous studies. Fourth, we conducted only a cross-
sectional analysis without assessing the impact of polypharmacy and STOPP/START criteria on 
patient’s related health outcomes Finally, our results may not be totally generalizable to primary care 
settings in general for several reasons: we could not assess other parameters of socioeconomic status, 
such as income and education, because of the lack of reliable information on these variables in the 
medical charts, and, in Switzerland, there are generally more forced migrants and patients with lower 
socioeconomic status in university primary care settings, which has been associated with an earlier 
occurrence of multimorbidity [3]. The prevalence of some comorbidities, like hypertension, may also be 
higher in these settings [32]. Furthermore, almost all patients were cared by residents at the end of their 
postgraduate training, who may be more adherent to medical guidelines [25]. 
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Learning points: 
Ø In university primary care settings, 37.0% of patients have ≥5 chronic drugs (4.1% ≥10), and 
potentially inappropriate prescribing is more frequent among participants with polypharmacy 
(11.9% vs. 3.7%, p<0.0001).  
Ø Several specific comorbidities, particularly hypertension, diabetes mellitus, chronic kidney 
disease and cardiovascular diseases, are strongly associated with polypharmacy. 
Ø Future trials should include multimorbid patients, in order to develop prescription guidelines 
adapted to this population at particular high risk of polypharmacy and potentially inappropriate 
prescribing. 
 
Conclusions and clinical implications 
In this random sample of primary care patients, we found that polypharmacy was highly prevalent in 
university primary care settings and strongly associated with age, multimorbidity, the number of 
comorbidities, and specific comorbidities, particularly hypertension, diabetes mellitus, chronic kidney 
disease, and cardiovascular diseases. This is clinically relevant, given the association of polypharmacy 
with adverse consequences, particularly in patients with multimorbidity [5]. Given that the prevalence of 
polypharmacy and multimorbidity will very probably further increase in the coming years, and that PIP is 
associated with polypharmacy, further randomized trials including multimorbid patients are needed in 
order to develop guidelines adapted to this particular population to help avoiding PIP and adverse drug 
events. As polypharmacy, the risk for drug-drug interactions and their associated negative 
consequences are significantly increased among the oldest old patients because of frailty and their 
higher number of comorbidities [54], future studies should also plan to include oldest old patients, i.e. 
those aged more than 80 years.Waiting for any new specific recommendation for multimorbid elderly, 
specific indications for each drug should be very carefully reviewed, particularly in those patients. In the 
meantime, we suggest that the process of prescription relies on the use of criteria developed to avoid 
PIP and PPO (e.g. the STOPP/START criteria [36, 39]), accounting for physician’s clinical judgment, 
estimated patient’s life expectancy and patient’s preferences. 
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Table 1.  Patient characteristics: overall and by presence or absence of polypharmacy. 
Characteristics Overall 
(n=1002)a 
0-4 drugs 
(n=631, 63.0%)a 
≥5 drugs 
(n=371, 37.0%)a 
p-valueb 
Age, mean (SD) 
Age groups, n (% per column) 
    50-54 
    55-59 
    60-64 
    65-69 
    70-74 
    75-80 
63.5 (8.3) 
 
197 (19.7) 
193 (19.3) 
186 (18.6) 
183 (18.3) 
128 (12.3) 
115 (11.5) 
62.2 (8.1) 
 
156 (24.7) 
125 (19.8) 
118 (18.7) 
106 (16.8) 
74 (11.7) 
52 (8.2) 
65.7 (8.0) 
 
41 (11.0) 
68 (18.3) 
68 (18.3) 
77 (20.8) 
54 (14.6) 
63 (17.0) 
<0.0001 
 
<0.0001 
<0.0001 
<0.0001 
0.03 
0.08 
0.31 
Women, n (% per column) 445 (44.4) 297 (47.1) 148 (39.9) 0.03 
Civil status, n (% per column) 
    married 
    single 
    divorced / separated 
    widow/-er 
 
506 (51.0) 
151 (15.2) 
233 (23.5) 
103 (10.4) 
 
314 (50.3) 
101 (16.2) 
150 (24.0) 
59 (9.5) 
 
192 (52.0) 
50 (13.6) 
83 (22.5) 
44 (11.9) 
 
<0.0001 
<0.0001 
<0.0001 
0.14 
Occupation, n (% per column) 
    Employed 
    Social aid  
    Unemployed  
    At home or in education 
    Retired  
 
285 (29.0) 
109 (11.1) 
101 (10.3) 
115 (11.7) 
372 (37.9) 
 
225 (36.3) 
60 (9.7) 
51 (8.2) 
79 (12.7) 
205 (33.1) 
 
60 (16.6) 
49 (13.5) 
50 (13.8) 
36 (9.9) 
167 (46.1) 
 
<0.0001 
0.29 
0.92 
<0.0001 
0.049 
Legal status, n (% per column) 
    Swiss 
    Resident permit 
    Forced migrant  
 
560 (55.9) 
325 (32.4) 
81 (8.1) 
 
362 (59.4) 
183 (30.2)  
61 (10.1) 
 
198 (55.0) 
142 (39.4) 
20 (5.6) 
 
<0.0001 
0.02 
0.002 
Number of outpatients visits over 2 years 
    Median (interquartile range) 
    Range, minimum-maximum 
 
10 (7-15) 
2-63 
 
9 (6-13) 
2-41 
 
12 (9-17) 
3-63 
 
<0.0001 
 
Never smoked, n (% per column)  283 (41.0) 194 (44.3) 89 (35.3) 0.02 
BMI, mean (SD) 28.8 (5.6) 27.9 (5.3) 30.4 (5.8) <0.0001 
Comorbiditiesc 
    mean (SD) 
    ≥2 comorbidities, n (% per column) 
 
2.6 (1.9) 
676 (67.5) 
 
1.9 (1.4) 
346 (54.8) 
 
3.7 (2.0) 
330 (89.0) 
 
<0.0001 
<0.0001 
Specific subgroupsd, n (% per column) 
   Psychiatric diseasese 
   Dementia 
   Cardiovascular diseasesf 
   Diabetes mellitus 
   Hypertension 
   Chronic pulmonary diseasesg 
   Cancer 
   Chronic kidney disease 
 
294 (29.3) 
24 (2.4) 
364 (36.3) 
292 (29.1) 
753 (75.1) 
261 (26.1) 
142 (14.2) 
167 (16.7) 
 
180 (28.5) 
14 (2.2) 
154 (24.4) 
113 (17.9) 
406 (64.3) 
148 (23.4) 
84 (13.3) 
61 (9.7) 
 
114 (30.7) 
10 (2.7) 
210 (56.6) 
179 (48.2) 
347 (93.5) 
113 (30.5) 
58 (15.6) 
106 (28.6) 
 
0.46 
0.63 
<0.0001 
<0.0001 
<0.0001 
0.02 
0.31 
<0.0001 
Inappropriate prescribing  
 Patients aged ≥65 yearsa  
   PIP, n (% per column) 
   PPO, n (% per column) 
 Whole population  
   PIP, n (% per column) 
   PPO, n (%  per column) 
 
 
25 (5.6) 
137 (32.2) 
 
67 (6.7) 
275 (27.5) 
 
 
7 (3.0) 
80 (34.5) 
 
23 (3.7) 
176 (28.0) 
 
 
18 (9.3) 
57 (29.4) 
 
44 (11.9) 
98 (26.4) 
 
 
0.006 
0.26 
 
<0.0001 
0.56 
 
Abbreviations: PIP, potentially inappropriate prescribing; PPO, potentially prescribing omission; SD, standard deviation; STOPP, Screening 
Tool of Older People’s Prescriptions; START, Screening Tool to Alert doctors to Right Treatment. 
a For the subset of patients aged ≥65 years that were applied the STOPP/START criteria: total n was 426, with 194 (45.6% with 
polypharmacy and 232 (54.5%) without polypharmacy. 
b p-value for comparison between patients with and without polypharmacy.  
c list of 17 comorbidities listed in Appendix table, full description in [32]. 
d record of ever having the listed comorbidity 
e depression, bipolar disorder, psychosis, schizophrenia, pervasive development disorder.  
f history of transient ischemic attack, cerebral vascular accident, coronary artery disease, angina, myocardial infarction, congestive heart 
failure or peripheral vascular disease. 
g chronic obstructive pulmonary disease, asthma, sleep apnea syndrome, sarcoidosis, pulmonary hypertension, bronchiectases, interstitial 
pulmonary disease or global respiratory insufficiency. 
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Table 2. Multivariate mixed-effects logistic regression analysis for the association 
between patient characteristics and polypharmacy. 
 
Variable Polypharmacy (≥5 drugs)  
OR 95% CI 
Age (years)a 
    50-54 (reference) 
    55-59 
    60-64 
    65-69 
    70-74 
    75-80 
 
1 
2.14 
2.16 
2.71 
2.78 
4.73 
 
- 
1.31-3.51 
1.30-3.59 
1.52-4.84 
1.46-5.27 
2.46-9.10 
Men 1.28 0.93-1.75 
Civil status 
    married (reference) 
    single  
    divorced / separated 
    widow/-er 
 
1 
0.79 
0.95 
1.01 
 
- 
0.52-1.21 
0.67-1.36 
0.63-1.61 
Occupation 
    Employed (reference) 
    Social aid  
    Unemployed 
    At home/in education 
    Retired  
 
1 
2.91 
3.89 
1.37 
1.74 
 
- 
1.76-4.81 
2.29-6.61 
0.77-2.44 
1.07-2.82 
Never smoked 0.76 0.52-1.11 
BMI (kg/m2), per unit 1.12 1.08-1.16 
Comorbiditiesb 
    Per each comorbidity 
    ≥2 comorbidities versus 0-1 comorbidity 
 
1.86 
6.14  
 
1.68-2.07 
4.16-9.08 
Specific subgroupsc 
   Psychiatric diseasesd 
   Dementia    
   Cardiovascular diseasese 
   Diabetes mellitus 
   Hypertension 
   Chronic pulmonary diseasesf 
   Cancer 
   Chronic kidney disease 
 
1.14 
0.83 
3.74 
4.47 
8.49 
1.29 
0.97 
3.96 
 
0.83-1.59 
0.35-2.01 
2.76-5.08 
3.23-6.20 
5.25-13.73 
0.94-1.76 
0.65-1.45 
2.71-5.80 
Inappropriate prescribing 
 Patients aged ≥65 years 
  Potentially inappropriate prescription 
  Potentially prescribing omission 
 Whole population 
  Potentially inappropriate prescription 
  Potentially prescribing omission 
 
 
3.72 
0.75 
 
 
3.64 
0.81 
 
 
1.47-9.44 
0.49-1.15 
 
 
2.07-6.39 
0.59-1.11 
 
The model was adjusted for age, gender, civil status, occupation. Random-effects model was used to account for 
treating physician.  
Some statistically significant variables in Table 1 lost significance because of the mixed-effects analysis. 
Abbreviations: BMI, body mass index; CI, confidence interval; OR, odds ratio. 
a for univariate and multivariate analysis p-value for trend <0.001. 
b list of 17 comorbidities listed in Appendix table, full description in [32]. 
c record of ever having the listed comorbidity. 
d depression, bipolar disorder, psychosis, schizophrenia, pervasive development disorder.  
e history of transient ischemic attack, cerebral vascular accident, coronary artery disease, angina, myocardial 
infarction, congestive heart failure or peripheral vascular disease. 
f chronic obstructive pulmonary disease, asthma, sleep apnea syndrome, sarcoidosis, pulmonary hypertension, 
bronchiectases, interstitial pulmonary disease or global respiratory insufficiency. 
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Table 3. Multivariate categorical mixed-effects regression analysis for the association 
with number of drugs as a count variable.  
 
 Number of drugs (count variable) 
Variable Incident rate 
ratio 
95% CI 
Age (years) 
    50-54 (reference) 
    55-59 
    60-64 
    65-69 
    70-74 
    75-80 
 
1 
1.27 
1.24 
1.30 
1.29 
1.29 
 
- 
1.11-1.45 
1.07-1.44 
1.10-1.53 
1.09-1.53 
1.07-1.56 
Male 1.11 1.01-1.22 
Civil status 
    married (reference) 
    single  
    divorced / separated 
    widow/-er 
 
1 
0.94 
0.97 
1.05 
 
- 
0.81-1.08 
0.86-1.08 
0.92-1.19 
Occupation 
    Employed (reference) 
    Social aid  
    Unemployed 
    At home/in education 
    Retired  
 
1 
1.55 
1.60 
1.27 
1.37 
 
- 
1.30-1.86 
1.37-1.87 
1.07-1.51 
1.18-1.58 
Never smoked 0.91 0.81-1.03 
BMI (kg/m2), per unit 1.03 1.02-1.04 
Comorbiditiesa 
    Each comorbidity  
    ≥2 comorbidities versus 0-1 comorbidity 
 
1.18 
1.91 
 
1.15-1.20 
1.72-2.13 
Specific subgroupsb 
   Psychiatric diseasec 
   Dementia    
   Cardiovascular diseased 
   Diabetes mellitus 
   Hypertension 
   Chronic pulmonary diseasee 
   Cancer 
   Chronic kidney disease 
 
1.11 
1.11 
1.48 
1.58 
2.10 
1.15 
1.01 
1.52 
 
1.00-1.23 
0.85-1.46 
1.35-1.63 
1.45-1.72 
1.87-2.36 
1.04-1.26 
0.89-1.14 
1.37-1.69 
Inappropriate prescribing 
 Patients aged ≥65 years 
  Potentially inappropriate prescription 
  Potentially prescribing omission 
Whole population 
  Potentially inappropriate prescription 
  Potentially prescribing omission 
 
 
1.35 
0.94 
 
1.44 
0.90 
 
 
1.12-1.64 
0.83-1.06 
 
1.26-1.64 
0.81-1.00 
 
The model was adjusted for age, gender, civil status, occupation. Random-effects model was used to account for 
treating physician. 
Some statistically significant variables in Table 1 lost significance because of the mixed-effects analysis. 
Abbreviations: BMI, body mass index; CI, confidence interval. 
a list of 17 comorbidities listed in Appendix table, full description in [32]. 
b record of ever having the listed comorbidity. 
c depression, bipolar disorder, psychosis, schizophrenia, pervasive development disorder.  
d history of transient ischemic attack, cerebral vascular accident, coronary artery disease, angina, myocardial 
infarction, congestive heart failure or peripheral vascular disease. 
e chronic obstructive pulmonary disease, asthma, sleep apnea syndrome, sarcoidosis, pulmonary hypertension, 
bronchiectases, interstitial pulmonary disease or global respiratory insufficiency. 
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Table 4. Number of patients with unfulfilled STOPP/START criteria.  
 
 Patients  
≥65 years, 
(n=426) 
All patients 
(n=1002) 
STOPP criteria 
A3. Any duplicate drug class prescription e.g. two concurrent 
NSAIDs, SSRIs, loop diuretics, ACE inhibitors, anticoagulants 
5 (1.2) 7 (0.7) 
B3. Beta-blocker in combination with verapamil or diltiazem 1 (0.2) 4 (0.4) 
B6. Loop diuretic as first-line treatment for hypertension 1 (0.2) 4 (0.4) 
C1. Long-term aspirin at doses greater than 160mg per day 8 (1.9) 17 (1.7) 
C7. Ticlopidine in any circumstances 0 (0.0) 0 (0.0) 
J1. Sulphonylureas with a long duration of action with type 2 
diabetes mellitus 
12 (2.8) 37 (3.7) 
J2. Thiazolidenediones in patients with documented heart failure 0 (0.0) 0 (0.0) 
START criteria 
A3. Antiplatelet therapy (aspirin or clopidogrel or prasugrel or 
ticagrelor) with a documented history of coronary, cerebral or 
peripheral vascular disease 
63 (14.8) 129 (12.9) 
A4. Antihypertensive therapy where systolic blood pressure 
consistently >160 mmHg and/or diastolic blood pressure 
consistently >90 mmHg; if systolic blood pressure >140 mmHg 
and /or diastolic blood pressure >90 mmHg, if diabetic 
15 (3.5) 53 (5.3) 
A5. Statin therapy with a documented history of coronary, 
cerebral or peripheral vascular disease, unless the patient’s 
status is end-of-life or age is >85 years. 
77 (18.1) 153 (15.3) 
A7. Beta-blocker with ischaemic heart disease. 43 (10.1) 72 (7.2) 
Abbreviations: STOPP, Screening Tool of Older People’s Prescriptions; START, Screening Tool to Alert doctors to Right 
Treatment. 
Data are presented as number (%) of patients. 
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Figure 1 Percentage of patients in ambulatory medicine receiving a particular number of drugs (0 to 
≥10),  stratified by a) age groups; b) number of comorbidities (0, 1, 2, 3-4, 5-6, ≥7), out of a list of 17 
selected comorbidities, based on a large study by Higashi et al. [33] and the Charlson index [34], as 
previously defined [32]. 
 
 
